Top Health Tech Companies in Belfast (24)
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability & Growth Strengths
Innovation-Driven Growth: New AI-focused capabilities (e.g., AI Connectors built on Model Context Protocol) and a stated push to be an “AI platform for biotech R&D” signal ongoing product investment. Reported usage of Benchling AI across 500 biotech companies underscores adoption of these innovations.
Strategic Partnerships: The January 2026 collaboration with Lilly’s TuneLab is positioned to bring proprietary models to scientists across Benchling’s customer base. Acqui-hires of ReSync Bio and Sphinx Bio in 2025 were used to accelerate the AI roadmap.
Strong Revenue Growth: ARR was independently estimated around the low-$200 millions by mid-2024 with year-over-year increases, indicating continued top-line expansion. While the pace has moderated versus earlier years, the trajectory remains positive.
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. We are 340,000 colleagues in two distinct and complementary businesses working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences. Optum delivers care aided by technology and data,...
UnitedHealth Group's Top Stability & Growth Strengths
Strong Market Position & Advantage: Rankings on the 2026 Fortune 500 and Global 500 reflect industry-leading revenue scale. AM Best identifies the company as the largest public insurer in the U.S./Canada, with Optum Rx among the "Big 3" PBMs.
Diversified Revenue Streams: A vertically integrated model spans UnitedHealthcare and Optum (Health, Insight, Rx), combining insurance, care delivery, pharmacy benefits, and analytics. This breadth supports performance across funding cycles and care settings.
Strong Revenue Growth: Consolidated revenue rose to about $447.6 billion in 2025 from $400.3 billion in 2024, and 2026 has delivered consecutive quarters around $112 billion while full-year earnings guidance was raised.
Blue Zinc is a technology company in the health industry, specialising in improving, connecting and automating the musculoskeletal and talking therapies arenas. We produce solutions for all parts of the market, from funders to practitioners.
Data Mastery is a data consultancy based in the Belfast and Dublin, helping organisations transform how they collect, model, and leverage data. We specialise in designing and delivering modern analytics solutions built on Azure, Microsoft Fabric and Power BI, enabling business users to make confident, data-informed decisions. Our approach is deeply consultative: we embed ourselves within client teams to understand business...
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with...
Stryker's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double-digit annual sales expansion through 2025, with management guiding to continued organic growth into 2026.
Strong Market Position & Advantage: Evidence highlights leadership in orthopedic robotics and top-tier standings among global medtech peers, with notable share in joint replacement and integrated OR technologies.
Diversified Revenue Streams: Multiple segments and recent vascular-focused acquisitions broaden growth drivers and reduce reliance on any single category.
Welcome! We are Northern Ireland’s Premier Private Healthcare Group. Our mission is to become a world-class provider of healthcare solutions by putting our patients to the forefront of everything we do. Our aim is to make the Kingsbridge Healthcare Group the preferred choice for both patients and healthcare professionals. Because Life Matters. Companies within the Kingsbridge Healthcare Group include: Kingsbridge...
We constantly hear how healthcare systems are under pressure or broken and that healthcare is mired in siloed systems. But what if the visible cracks in healthcare were actually symptoms of not embracing the digital transformation other industries have used to flourish? Not giving our frontline heroes the tools required to do their job? What if we reimagined how care...
Lantum is a workforce management platform that makes it easier for healthcare providers to mobilise their workforce, and for clinicians to work more flexibly. Our Connected Scheduling platform gives you a staff bank, rota tool and a clinician network all in one place to improve fill rates, cut admin time, and reduce costs. We started life as Network Locum in...
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 20,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology,...
Henry Schein's Top Stability & Growth Strengths
Strong Market Position & Advantage: Regulators, company filings, and independent coverage characterize Henry Schein as a top full‑service dental distributor with global scale and Fortune 500 standing. Its role in an FTC‑recognized oligopoly and breadth across distribution and software reinforce durable competitive advantages.
Resilient & Sustainable Growth: Recent results indicate steady year‑over‑year increases in sales and EPS, and management has reaffirmed guidance for modest top‑line and EBITDA growth. Share repurchases and a multi‑year operating‑income improvement program support a measured compounding profile.
Future-Ready Strategy: The company is investing in higher‑growth technology and value‑added services and pursuing AI‑enabled initiatives alongside a defined multi‑year operating plan. Portfolio moves in software, digital solutions, and specialty offerings are positioned to create switching costs and embed workflows in practices.
We are a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, extraordinary talent and innovation, we ‘create better together’ by partnering with healthcare professionals. Our extensive range of products, services and integrated technologies fuel active lifestyles.
Enovis's Top Stability & Growth Strengths
Strong Revenue Growth: Full-year 2025 revenue reached about $2.2–$2.248B, described as up year over year with organic growth also cited, and 2026 guidance indicates continued expansion. Multi-year net sales progression from 2023 to 2025 is presented as consistently upward, with Reconstructive repeatedly cited as the primary growth engine.
Innovation-Driven Growth: The company is characterized as innovation-driven, highlighting investments such as the ARVIS Gen 2 augmented reality system and a steady cadence of new product launches across reconstructive and prevention/recovery offerings. Digital enablement and technology differentiation are framed as key enablers of share gains, especially in faster-growing niches like extremities/shoulder.
Strong Market Position & Advantage: Category leadership is asserted in bracing and rehab through legacy DJO brands (DonJoy, Aircast, Chattanooga), and the LimaCorporate acquisition is described as elevating the company into a top-tier position in extremities. The portfolio is positioned as strong in select segments even if not dominant across the entire orthopedic implant market.
ResMed provides medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
ResMed's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.
Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.
Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.
Healthcare is complex enough, finding the knowledge you need shouldn’t be. Eolas Medical is a knowledge management platform for clinicians, enabling instant access to information at the point of care. The platform is used by NHS Trusts, clinical teams, and individuals to support the delivery of patient care by consolidating and organising medical knowledge from trusted sources into a simple, easy-to-use...
At Elanco, we work to improve the health of animals through innovative products and services for pets and farm animals around the world. As a global animal health company, we provide solutions that empower our customers to advance a vision of Food and Companionship Enriching Life. Since 1954, Elanco has committed to empowering veterinarians, farmers, and all those who care...
Elanco's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is growing year over year with acceleration in the latest quarter, and guidance indicates continued organic expansion into 2026.
Innovation-Driven Growth: Innovation revenue surpassed targets and management raised the next-year goal, supported by new launches such as Befrena, Credelio Quattro, Zenrelia, AdTab, and Experior.
Future-Ready Strategy: A multi‑year plan calls for ongoing organic growth and improving earnings metrics, underpinned by a late‑stage pipeline expected to deliver multiple potential blockbusters through 2026–2031.
The world needs to train 18 million more healthcare professionals by 2030. At MedAll we’re on a mission to solve this healthcare crisis by making great healthcare training more accessible to every healthcare professional, everywhere. Read more about our mission at MedAll.org/mission
Locate a Locum uses innovative marketplace technology through a website and app to mobilise the world's healthcare workforce. Locate a Locum has helped drive a digital revolution in healthcare. As well as working in a day-to-day capacity to place healthcare workers, Locate a Locum also has a business solution that provides healthcare workforce management, including Rota, Leave, Time & Attendance, Payments,...
ESO is a fast-paced, growing data, technology, and research company passionate about improving community health and safety through the power of data. We pioneer innovative, user-friendly software to meet the changing needs of today’s EMS agencies, fire departments, and hospitals. We’re small enough to be nimble and fun, but big enough to be a great place to work. We serve...
ESO's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is positioned as an industry leader in EMS/fire software with broad adoption across agencies and hospitals, supported by a large data footprint and visibility in public-sector deployments.
Investor Backing & Capital Strength: Strategic investment backing from Vista Equity Partners (and references to other PE support) is presented as enabling accelerated investment in customer experience and technical innovation.
Innovation-Driven Growth: The product suite highlights differentiated interoperability and analytics capabilities (e.g., HDE, standards transitions, indices/research outputs) and continued feature releases and platform expansion that align with ongoing growth signals.
Affidea is a pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider, operating in Greece since 2005 to offer high-quality, integrated primary health services.
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and...
Sanofi's Top Stability & Growth Strengths
Strong Revenue Growth: Sales growth is described as strong, with 2025 net sales up at constant exchange rates and Q4 showing further acceleration, indicating momentum into 2026.
Profitability: Earnings expansion is described as outpacing sales growth in 2025, and 2026 guidance indicates continued profitable expansion with EPS growing slightly faster than sales.
Product Line Growth: Newer launches are scaling rapidly, with notable growth in recent pharma launches and contributions from products beyond the flagship franchise, helping broaden growth drivers.
10,000 people, one global focus - enhancing the health and well-being of pets, people, and livestock. We are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of...
IDEXX's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double‑digit top‑line increases in 2025 and early 2026, with Q1 and Q2 2026 up 14% and 10% reported, respectively, and full‑year 2026 revenue guidance raised. Growth is broad‑based across Companion Animal Group diagnostics, Water, and LPD.
Profitability: Margin expansion is attributed to recurring diagnostics volume, pricing, and productivity, translating into higher EPS and operating leverage. Guidance and quarterly updates highlight continued earnings growth if these drivers are maintained.
Strong Market Position & Advantage: The company is widely regarded as the category leader in companion‑animal diagnostics, reinforced by an integrated ecosystem of instruments, consumables, labs, imaging, and software. Independent analyses consistently place it at or near the top across key diagnostics segments, supporting durable advantage.
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
